Recent studies have centered on the overlap of GLP-1|GIP|GCGR stimulant therapies and DA communication. While GCGR stimulators are increasingly employed for managing type 2 diabetes, their emerging consequences on reward circuits, specifically governed by dopaminergic networks, are attracting considerable interest. This article provides a brief ass